MREO
Price:
$3.39
Market Cap:
$524.55M
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-64...[Read more]
Industry
Biotechnology
IPO Date
2019-04-24
Stock Exchange
NASDAQ
Ticker
MREO
According to Mereo BioPharma Group plc’s latest financial reports and current stock price. The company's current PE Ratio is -11.30. This represents a change of -70.62% compared to the average of -38.47 of the last 4 quarters.
The mean historical PE Ratio of Mereo BioPharma Group plc over the last ten years is -5.62. The current -11.30 PE Ratio has changed 19.99% with respect to the historical average. Over the past ten years (40 quarters), MREO's PE Ratio was at its highest in in the March 2021 quarter at 58.34. The PE Ratio was at its lowest in in the March 2024 quarter at -66.69.
Average
-5.62
Median
-10.25
Minimum
-51.70
Maximum
66.37
Discovering the peaks and valleys of Mereo BioPharma Group plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 290.78%
Maximum Annual PE Ratio = 66.37
Minimum Annual Increase = -Infinity%
Minimum Annual PE Ratio = -51.70
Year | PE Ratio | Change |
---|---|---|
2023 | -51.70 | 290.78% |
2022 | -13.23 | -119.93% |
2021 | 66.37 | -998.19% |
2020 | -7.39 | -12.14% |
2019 | -8.41 | -41.75% |
2018 | -14.44 | 24.88% |
2017 | -11.56 | 12.74% |
2016 | -10.25 | -Infinity% |
The current PE Ratio of Mereo BioPharma Group plc (MREO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0.48
5-year avg
-2.87
10-year avg
-5.62
Mereo BioPharma Group plc’s PE Ratio is less than Terns Pharmaceuticals, Inc. (-5.24), less than PDS Biotechnology Corporation (-1.52), less than Inozyme Pharma, Inc. (-1.97), less than HOOKIPA Pharma Inc. (-0.59), greater than Day One Biopharmaceuticals, Inc. (-14.55), less than X4 Pharmaceuticals, Inc. (-6.92), less than Acumen Pharmaceuticals, Inc. (-1.30), less than Amylyx Pharmaceuticals, Inc. (-1.07), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Elevation Oncology, Inc. (-0.81), less than Hepion Pharmaceuticals, Inc. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-5.24 | $503.69M | |
-1.52 | $62.47M | |
-1.97 | $193.36M | |
-0.59 | $19.60M | |
-14.55 | $1.28B | |
-6.92 | $98.42M | |
-1.30 | $106.34M | |
-1.07 | $278.99M | |
-0.00 | $941.00 | |
-0.81 | $33.90M | |
-0.15 | $3.48M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mereo BioPharma Group plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mereo BioPharma Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Mereo BioPharma Group plc's PE Ratio?
How is the PE Ratio calculated for Mereo BioPharma Group plc (MREO)?
What is the highest PE Ratio for Mereo BioPharma Group plc (MREO)?
What is the 3-year average PE Ratio for Mereo BioPharma Group plc (MREO)?
What is the 5-year average PE Ratio for Mereo BioPharma Group plc (MREO)?
How does the current PE Ratio for Mereo BioPharma Group plc (MREO) compare to its historical average?